| Attribute |
Value |
| 52 Week Change |
0.35641026 |
| Address1 |
99 Coolidge Avenue |
| Address2 |
Suite 500 |
| All Time High |
28.265 |
| All Time Low |
2.7 |
| Ask |
6.4 |
| Ask Size |
2 |
| Audit Risk |
4 |
| Average Daily Volume10 Day |
145,020 |
| Average Daily Volume3 Month |
159,911 |
| Average Volume |
159,911 |
| Average Volume10Days |
145,020 |
| Beta |
3.112 |
| Bid |
3.77 |
| Bid Size |
2 |
| Board Risk |
6 |
| Book Value |
-1.915 |
| City |
Watertown |
| Compensation As Of Epoch Date |
1,735,603,200 |
| Compensation Risk |
8 |
| Country |
United States |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
5.29 |
| Current Ratio |
2.733 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,774,915,200 |
| Day High |
5.3 |
| Day Low |
4.99 |
| Display Name |
Foghorn Therapeutics |
| Earnings Timestamp |
1,773,259,200 |
| Earnings Timestamp End |
1,778,788,800 |
| Earnings Timestamp Start |
1,778,788,800 |
| Ebitda |
-78,775,000 |
| Ebitda Margins |
-2.54861 |
| Enterprise To Ebitda |
-2.449 |
| Enterprise To Revenue |
6.241 |
| Enterprise Value |
192,900,304 |
| Eps Current Year |
-1.132 |
| Eps Forward |
-0.91143 |
| Eps Trailing Twelve Months |
-1.18 |
| Esg Populated |
0 |
| Exchange |
NGM |
| Exchange Data Delayed By |
0 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fifty Day Average |
5.2204 |
| Fifty Day Average Change |
0.069600105 |
| Fifty Day Average Change Percent |
0.0133323325 |
| Fifty Two Week Change Percent |
35.641026 |
| Fifty Two Week High |
6.95 |
| Fifty Two Week High Change |
-1.6599998 |
| Fifty Two Week High Change Percent |
-0.23884891 |
| Fifty Two Week Low |
3.27 |
| Fifty Two Week Low Change |
2.02 |
| Fifty Two Week Low Change Percent |
0.617737 |
| Fifty Two Week Range |
3.27 - 6.95 |
| Financial Currency |
USD |
| First Trade Date Milliseconds |
1,603,459,800,000 |
| Float Shares |
28,680,940 |
| Forward Eps |
-0.91143 |
| Forward P E |
-5.804066 |
| Free Cashflow |
-35,229,876 |
| Full Exchange Name |
NasdaqGM |
| Full Time Employees |
106 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Governance Epoch Date |
1,775,001,600 |
| Gross Margins |
-1.76508 |
| Gross Profits |
-54,557,000 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.17994 |
| Held Percent Institutions |
0.72029 |
| Implied Shares Outstanding |
58,700,246 |
| Industry |
Biotechnology |
| Industry Disp |
Biotechnology |
| Industry Key |
biotechnology |
| Ipo Expected Date |
2,020-10-23 |
| Is Earnings Date Estimate |
1 |
| Language |
en-US |
| Last Fiscal Year End |
1,767,139,200 |
| Long Business Summary |
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. |
| Long Name |
Foghorn Therapeutics Inc. |
| Market |
us_market |
| Market Cap |
310,524,320 |
| Market State |
PRE |
| Max Age |
86,400 |
| Message Board Id |
finmb_538076136 |
| Most Recent Quarter |
1,767,139,200 |
| Net Income To Common |
-74,283,000 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
310,524,301 |
| Number Of Analyst Opinions |
9 |
| Open |
4.99 |
| Operating Cashflow |
-86,099,000 |
| Operating Margins |
-2.1191702 |
| Overall Risk |
6 |
| Payout Ratio |
0.0 |
| Phone |
617-586-3100 |
| Previous Close |
4.86 |
| Price Eps Current Year |
-4.673145 |
| Price Hint |
2 |
| Price To Book |
-2.762402 |
| Price To Sales Trailing12 Months |
10.046405 |
| Profit Margins |
-2.40328 |
| Quick Ratio |
2.66 |
| Quote Source Name |
Nasdaq Real Time Price |
| Quote Type |
EQUITY |
| Recommendation Key |
none |
| Region |
US |
| Regular Market Change |
0.43 |
| Regular Market Change Percent |
8.84773 |
| Regular Market Day High |
5.3 |
| Regular Market Day Low |
4.99 |
| Regular Market Day Range |
4.99 - 5.3 |
| Regular Market Open |
4.99 |
| Regular Market Previous Close |
4.86 |
| Regular Market Price |
5.29 |
| Regular Market Time |
1,776,456,001 |
| Regular Market Volume |
153,164 |
| Return On Assets |
-0.21290001 |
| Revenue Growth |
2.238 |
| Revenue Per Share |
0.491 |
| Sand P52 Week Change |
0.38150132 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Share Holder Rights Risk |
5 |
| Shares Outstanding |
58,700,246 |
| Shares Percent Shares Out |
0.0227 |
| Shares Short |
1,329,548 |
| Shares Short Previous Month Date |
1,772,150,400 |
| Shares Short Prior Month |
1,179,397 |
| Short Name |
Foghorn Therapeutics Inc. |
| Short Percent Of Float |
0.0336 |
| Short Ratio |
6.93 |
| Source Interval |
15 |
| State |
MA |
| Symbol |
FHTX |
| Target High Price |
14.0 |
| Target Low Price |
9.0 |
| Target Mean Price |
11.44444 |
| Target Median Price |
12.0 |
| Total Cash |
158,894,000 |
| Total Cash Per Share |
2.707 |
| Total Debt |
41,270,000 |
| Total Revenue |
30,909,000 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.0 |
| Trailing Annual Dividend Yield |
0.0 |
| Trailing Eps |
-1.18 |
| Trailing Peg Ratio |
None |
| Triggerable |
1 |
| Two Hundred Day Average |
5.0901 |
| Two Hundred Day Average Change |
0.19990015 |
| Two Hundred Day Average Change Percent |
0.039272346 |
| Type Disp |
Equity |
| Volume |
153,164 |
| Website |
https://foghorntx.com |
| Zip |
2,472 |